Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market

There is currently no approved vaccine for RSV, which causes serious illness and can be deadly for newborns and the elderly. The race to come first to the vaccine market is heating up, while more companies are close to completing phase III studies. Get an overview of their progress here.

Photo: Pedro Pardo/AFP/Ritzau Scanpix

Respiratory Syncytical Virus, or RSV, causes a respiratory infection. It might not sound dangerous, but it can be.

Just like with the flu, young babies and the elderly are vulnerable to the virus, which causes the hospitalization of 3 million babies and around 336,000 elderly people a year, according to medical journal Nature.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs